Nashville, Tenn. — November 3, 2025 — Leads & Copy — Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) will report its third quarter 2025 financial results after market close on Monday, November 10, 2025. A live Zoom webinar will be hosted at 2:00 pm PT / 5:00 pm ET that same day to discuss the results.
The webinar, including a Q&A session, can be accessed via registration at iMDX Q3 2025 Earnings Webinar. An archived replay will be available on iMDX’s investor relations website at https://investors.imdxinc.com/ after the call.
Separately, CEO Josh Riggs will attend the Stephens NASH25 Conference, from November 18-20, 2025, on November 19th. Investors can book one-on-one meetings with management by contacting their Stephens sales representative.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), aims to democratize access to novel molecular diagnostic testing. iMDx utilizes a proprietary approach to quantify dd-cfDNA, a molecular biomarker of transplant rejection.
iMDx™, GraftAssure™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025.
Doug Farrell, LifeSci Advisors LLC, dfarrell@lifesciadvisors.com
Source: Insight Molecular Diagnostics Inc.
